Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 1/20 | 0.61 |
| ▸ | GCGR | P47871 | 1/20 | 0.61 |
| ▸ | GIPR | P48546 | 1/20 | 0.61 |
| ▸ | IL23R | Q5VWK5 | 12/20 | 0.61 |
| ▸ | CD47 | Q08722 | 1/20 | 0.56 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.56 |
| ▸ | GHSR | Q92847 | 2/20 | 0.56 |
| ▸ | NPY2R | P49146 | 1/20 | 0.56 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16692898 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL16692899 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL19731216 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL19731206 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL16692892 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL24172454 | 0.99 | IL23R (0.61) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL21185972 | 0.96 | IL23R (0.65) | IL23RKISS1R | |
| SCHEMBL20993012 | 0.94 | GLP1R (0.68) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL26246781 | 0.93 | IL23R (0.54) | GLP1RGCGRGIPRIL23RCD47 | |
| SCHEMBL30092992 | 0.92 | IL23R (0.62) | IL23RCD47KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759843-B2 | Method and pharmaceutical composition for use in the treatment of cancer | Karoyan, Philippe (FR) | 2020-09-01 | — | — | US | disclosed |
| US-20190135898-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2019-05-09 | — | — | US | disclosed |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | UNIVERSITE PARIS DIDEROT- PARIS 7 (FR) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135898-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF CANCER | KLKB1, KLK5, KLK1 | GLP1R 469/4885GCGR 1041/4885GIPR 223/4885 |
| US-20170362302-A1 | Method and Pharmaceutical Composition for Use in the Treatment of Cancer | KLKB1, KLK5, KLK1 | GLP1R 469/4885GCGR 1041/4885GIPR 223/4885 |
| US-10759843-B2 | Method and pharmaceutical composition for use in the treatment of cancer | KLKB1, KLK5, KLK1 | GLP1R 469/4885GCGR 1041/4885GIPR 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.